Joshua et al. (2012) found that HNSCC primary tumors with elevated CD44+ cells (>36%) had an increased risk of recurrence of their primary tumor compared to tumors with lower CD44+ levels (<15%). This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.